Aroa Biosurgery's gross profit for the
six
months ended in Mar. 2024 was A$29.83 Mil. Aroa Biosurgery's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was A$54.10 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Aroa Biosurgery's gross profit for the
six
months ended in Mar. 2024 was A$29.83 Mil. Aroa Biosurgery's Revenue for the
six
months ended in Mar. 2024 was A$34.38 Mil. Therefore, Aroa Biosurgery's Gross Margin % for the quarter that ended in Mar. 2024 was 86.75%.
Aroa Biosurgery had a gross margin of 86.75% for the quarter that ended in Mar. 2024 => Durable competitive advantage
During the past 5 years, the highestGross Margin % of Aroa Biosurgery was 85.39%. The lowest was 69.48%. And the median was 80.39%.
Aroa Biosurgery Gross Profit Historical Data
The historical data trend for Aroa Biosurgery's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aroa Biosurgery's Gross Profit
For the Medical Devices subindustry, Aroa Biosurgery's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Gross Profit distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Gross Profit falls into.
Aroa Biosurgery Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Aroa Biosurgery's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$54.10 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aroa Biosurgery had a gross margin of 86.75% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Aroa Biosurgery Gross Profit Related Terms
Thank you for viewing the detailed overview of Aroa Biosurgery's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:ARX has been successfully added to your